Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial

Michael Boehm,J. Butler,G. Filippatos,J. P. Ferreira, S. J. Pocock,A. Abdin, F. Mahfoud, M. Brueckmann, I. Saloustros, E. Schueler,P. Ponikowski,C. Wanner,F. Zannad,M. Packer,S. D. Anker

EUROPEAN JOURNAL OF HEART FAILURE(2022)

引用 0|浏览10
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要